5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics

Serotonin (5-hydroxytryptamine; 5-HT) 2A receptor (5-HT2AR) signaling is essential for the actions of classical psychedelic drugs. In this study, we examined whether sequence variations in the 5-HT2AR gene affect the signaling of four commonly used psychedelic drugs. We examined the in vitro pharmacology of seven non-synonymous single-nucleotide polymorphisms (SNPs), which give rise to Ser12Asn, Thr25Asn, Asp48Asn, Ile197Val4.47, Ala230Thr, Ala447Val, and His452Tyr variant 5-HT2A serotonin receptors. We found that these non-synonymous SNPs exert statistically significant, although modest, effects on the efficacy and potency of four therapeutically relevant psychedelics. Significantly, the in vitro pharmacological effects of the SNP drug actions at 5-HT2AR are drug specific.

5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics

Excerpts from the publication

Read more

Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review

Psilocybin-assisted psychotherapy for Parkinson’s disease without depression: A case-report

Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review

Prevalence and associations of classic psychedelic-related seizures in a population-based sample

Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents

The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis